KR101598668B1 - Composition comprising alcohol extracts from clavicorona pyxidata for treating or preventing hyperlipidemia - Google Patents

Abstract

More particularly, the present invention relates to an alcohol extract which is effective for the treatment and prevention of hyperlipidemia and which can be used for the treatment and prevention of obesity, as an active ingredient.
The composition comprising the alcohol extract of the present invention as an active ingredient may inhibit the activity of pancreatic cholesterol esterase or pancreatic lipase and may be useful for the treatment or prevention of hyperlipidemia.

Description

FIELD OF THE INVENTION The present invention relates to a composition for treating or preventing hyperlipidemia,

More particularly, the present invention relates to a composition for treating or preventing hyperlipidemia, which comprises an alcoholic extract of Alaska pollack mushroom effective for the treatment and prevention of hyperlipidemia.

Hyperlipidemia refers to a disease of high blood fat content. Generally, when total cholesterol is over 240 ㎎ / dl or triglycerides are over 200 ㎎ / dl, it is called hyperlipidemia. Hyperlipidemia is known to be a major cause of hypertension, myocardial infarction, and stroke due to cholesterol blocks the blood vessels and inhibits blood circulation.

BACKGROUND ART In order to prevent or treat hyperlipidemia due to cholesterol, studies have been made on substances that inhibit the absorption of cholesterol. Currently, statin drugs are widely used for the treatment of hyperlipidemia due to inhibition of cholesterol absorption. The drug in this series is an inhibitor of Hmg-CoA reductase and has the effect of inhibiting cholesterol synthesis and lowering blood LDL-cholesterol. In addition, ezetimibe, niacin and fibrate preparations are mainly used. However, there is a possibility that side effects such as myalgia, constipation or digestive disorder and hepatic dysfunction are rarely observed when the drug is administered.

In PCT / KR2012 / 10604, it has been disclosed that the alcohol extract of Pseudomonas aeruginosa can inhibit the activity of pancreatic cholesterol ester raise and lower the absorption of cholesterol, thereby being used as a composition for treating and preventing hyperlipidemia.

In PCT / KR2012 / 10612, it has been disclosed that the water extract of red mulberry can inhibit the activity of pancreatic cholesterol ester raise and lower the absorption of cholesterol, thereby being used as a composition for treating and preventing hyperlipemia.

In PCT / KR2012 / 10550, it has been disclosed that the alcohol extract of the flower shield mushroom can inhibit the activity of pancreatic cholesterol ester raise and lower the absorption of cholesterol, thereby being used as a composition for treating and preventing hyperlipidemia.

On the other hand, in order to treat and prevent hyperlipidemia due to triglyceride, studies have been made on drugs having a mechanism of action that acts on digestive enzymes and inhibits the absorption of fat.

Xenical ^TM (orlistat) is well known as a typical drug. It inhibits the activity of TGL by covalent bonding with serine, which is the active site of triglyceride lipase (TGL), and prevents the fat from being degraded and absorbed .

"Development of specific egg yolk antibodies to the pancreatic lipase domain for obesity inhibition" Kor. J. Microbiol. Biotechnol. Vol. 36, No. 4, 299? 306 (2008) proposes a method of inhibiting the absorption of fat by inhibiting the activity of pancreatic lipase using a specific egg yolk antibody.

In PCT / KR2012 / 10558, it has been disclosed that the alcohol extract of yellow vanda mushroom can be used as a composition for treating and preventing obesity by inhibiting the activity of pancreatic lipase.

In PCT / KR2012 / 10602, it has been disclosed that water extract of Chrysanthemum morbus Mushroom can be used as a composition for treating and preventing obesity by inhibiting the activity of pancreatic lipase.

On the other hand, in PCT / KR2012 / 10621, water extract of acacia mushroom suppresses the activity of pancreatic lipase and the activity of raising pancreatic cholesterol ester, and it is known that it can inhibit fat absorption.

However, there is a continuing need for a new mushroom extract which can inhibit the absorption of fat and cholesterol and effectively prevent hyperlipidemia and obesity.

A problem to be solved by the present invention is to provide a novel mushroom extract which can inhibit the absorption of fat and cholesterol without showing any side effects in vivo.

Another object of the present invention is to provide a novel mushroom extract which can inhibit the activity of raising pancreatic cholesterol ester and the activity of pancreatic lipase.

A problem to be solved by the present invention is to provide a composition capable of inhibiting the absorption of fat and cholesterol and treating or preventing hyperlipidemia.

In order to accomplish the above object, the present invention provides a composition for treating or preventing hyperlipidemia comprising an alcohol extract having 1 to 10 carbon atoms in a mushroom.

The present invention provides a medicament for treating or preventing hyperlipidemia, which comprises an alcohol extract having 1 to 10 carbon atoms in Alfalfa mushroom as an active ingredient.

The present invention provides a method for treating or preventing hyperlipidemia comprising administering to an animal an alcoholic extract having 1 to 10 carbon atoms in a mushroom.

The present invention provides a health functional food for improving or preventing hyperlipidemia, which comprises an alcohol extract having 1 to 10 carbon atoms in Alaska pollack mushroom as an active ingredient.

The present invention also provides a composition for inhibiting the activity of raising pancreatic cholesterol ester, which comprises an alcohol extract having 1-10 carbon atoms of Alaska pollack as an active ingredient.

The present invention provides a medicament for inhibiting the activity of raising pancreatic cholesterol ester, which comprises an alcohol extract having 1 to 10 carbon atoms of Alaska pollack mushroom as an active ingredient.

The present invention provides a method for inhibiting the activity of pancreatic cholesterol esterase, comprising administering to an animal an alcoholic extract having 1 to 10 carbon atoms in a mushroom.

The present invention provides a health-functional food for inhibiting the activity of raising pancreatic cholesterol ester comprising an alcohol extract having 1-10 carbon atoms of Alaska pollack as an active ingredient.

Also, the present invention provides a composition for inhibiting the activity of pancreatic lipase comprising an alcohol extract having 1 to 10 carbon atoms in Alaska pollack as an active ingredient.

The present invention provides a medicament for inhibiting the activity of pancreatic lipase comprising an alcohol extract having 1 to 10 carbon atoms in the mushroom of the present invention as an active ingredient.

The present invention provides a method for inhibiting the activity of pancreatic lipase comprising the step of administering to an animal an alcohol extract having 1 to 10 carbon atoms in a mushroom.

The present invention provides a health-functional food for inhibiting the activity of pancreatic lipase comprising an alcohol extract having 1 to 10 carbon atoms of Alaska pollack mushroom as an active ingredient.

In addition, the present invention can be used as a composition for preventing and treating obesity by inhibiting the absorption of fat by inhibiting the activity of pancreatic lipase,

In the present invention,Clavicorona pyxidata(Fr.) Doty) is a mushroom belonging to the genus Cryptococcus From summer to autumn? It occurs in decayed trees. It is coral type with many branches and the end of the branch is crown shaped. It occurs from rotten wood and is easily distinguishable from other mushrooms.

In the present invention, the extract of Alnus japonicus, especially Alcoholic extract of Alnus japonica, lowers the activity of pancreatic cholesterol ester raise and effectively inhibits the activity of triglyceride lipase (TGL), pancreatic lipase To replace drugs that treat or prevent hyperlipidemia.

In the present invention, the alcohol extract of Cryptomeria japonica having 1 to 10 carbon atoms may be one obtained by extracting low-valent alcohol having 1 to 5 carbon atoms as an extraction solvent. When extracting low-mushroom with low-carbon alcohol having 1 to 5 carbon atoms, it exhibits excellent digestion and absorption inhibition effect of the body fat.

Particularly, as such an alcohol extracting solvent, a lower alcohol having 1 to 5 carbon atoms, more preferably ethanol, and most preferably 90 to 99.99% (v / v) ethanol can be used.

In the present invention, the weight or weight of the mushroom is understood to refer to the weight or weight of the dried mushroom unless otherwise noted.

On the other hand, the alcoholic extract of the above-mentioned mushroom can be produced according to a conventional method for producing a plant extract. Preferably, after removing the residues after drying and crushing the bark mushroom, 0.1 to 20 g of the pulverized product is added to 100 ml of the alcohol having 1 to 10 carbon atoms, more preferably, 1 to 20 g of the pulverized product per 100 ml of the extraction solvent, 5 g may be added to the solution. When the content of the crushed mushroom is too small compared to the extraction solvent, the effect of the mushroom is not sufficient, and when the amount of the crushed mushroom is excessively large relative to the amount of the extraction solvent, the effect of the increase in the content is not great It is not preferable from the viewpoint of productivity because the production cost is increased.

In this case, the extraction conditions are not limited, but preferably, the mushroom is mixed with an alcohol having 1 to 10 carbon atoms, which is an extraction solvent, at a temperature of 20 to 60 ° C for 12 to 36 hours, more preferably 30 To 40 < 0 > C for 20 to 24 hours.

Extraction at an excessively low temperature condition requires a long time for extracting an active ingredient, and extraction at an excessively high temperature may deteriorate the activity, which is undesirable.

When the extraction time is too short, the concentration of the effective component to be extracted is low, and when the extraction is performed for an excessively long time, the concentration of the extraction effective ingredient increases with the increase of the extraction time.

Then, the alcohol extract of the mushroom extract obtained by the above method is filtered through a filter cloth, etc., and the filtrate is centrifuged to remove the precipitate, followed by concentration under reduced pressure or concentration, followed by lyophilization.

On the other hand, the content of the alcoholic extract of mushroom mushroom, which is an active ingredient of the above-described embodiment of the composition for treating or preventing obesity and hyperlipidemia, is not limited, but may be preferably 0.001 to 50% by weight. When the content of the alcoholic extract of the mushroom is less than 0.001% by weight, digestion and absorption of the fat in the body are insignificant. When the content is more than 50% by weight, the effect of increasing the inhibitory activity is insignificant It is not economical. More preferably, the content of the alcoholic extract of Alaska pollack may be 0.01 to 50% by weight, and most preferably 0.1 to 30% by weight.

The present invention provides a medicament for the treatment or prevention of hyperlipidemia or obesity, which comprises an alcoholic extract of Alaska pollack mushroom contained in the above composition as an active ingredient. The medicinal product containing the alcohol extract of Alaska pollack as an active ingredient may further contain suitable carriers, excipients and diluents conventionally used in the production thereof.

Examples of carriers, excipients, and diluents that can be included in the medicament containing the alcohol extract of the present invention as an active ingredient include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, , Alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil have.

The medicinal product containing the alcohol extract of Alaska pollack mushroom of the present invention as an active ingredient can be used as oral formulations such as powders, granules, tablets, suspensions, emulsions and syrups according to a conventional method.

The oral formulations are meant to include solid and liquid formulations for oral administration and solid formulations for oral administration may include tablets, pills, powders, granules, capsules and the like, For example, starch, calcium carbonate, sucrose or lactose, gelatin and the like in combination with at least one excipient. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweetening agents, have.

The preferred dosage of the composition containing the alcoholic extract of Alaska pollack mushroom of the present invention varies depending on the condition and body weight, the degree of disease, the drug form, the administration route and the period, but can be appropriately selected by those skilled in the art. Preferably, the medicinal product containing the alcohol extract of the present invention as an active ingredient is 0.0001 to 100 mg / kg per day on the basis of the amount of the alcohol extract of Alaska pollack mushroom, and more preferably 0.01 to 10 mg / Mg / kg < / RTI > The administration may be carried out once a day or divided into several doses. The dose and the number of administrations do not limit the scope of the present invention in any aspect.

According to another embodiment of the present invention, there is provided a health functional food for improving or preventing hyperlipidemia or obesity, which comprises an alcohol extract of Alaska pollack as an active ingredient. Herein, the term " health functional food " means a natural product or a processed product containing one or more nutrients, preferably a state of being able to be directly eaten through a certain processing step.

Examples of the health functional food to which the alcohol extract of Alaska pollack mushroom of the present invention can be added include various foods, beverages, gums, tea, vitamin complex, and the like. In addition, in the present invention, the food may contain special nutritional foods (eg, crude oil, infant formula, etc.), meat products, fish products, tofu, mackerel, noodles (eg, (Such as soy sauce, soybean paste, hot pepper paste, mixed sauce), sauces, confectionery (eg snacks), dairy products (eg fermented milk, cheese), other processed foods, kimchi, pickled foods (For example, fruits and vegetables, beverages, fermented beverages, etc.), natural seasonings (eg, ramen soup, etc.). The food, beverage or food additive may be prepared by a conventional production method.

In the present specification, the functional food refers to a food group which is imparted with added value to function and express the function of the food by using physical, biochemical, biotechnological techniques, etc., Means a food which is processed and designed so that the body control function related to restoration and the like is sufficiently expressed to the living body. The functional food may include a food-acceptable food-aid additive, and may further comprise suitable carriers, excipients and diluents conventionally used in the production of functional foods.

In the present specification, beverage means a generic term for drinking or enjoying a taste and is intended to include a functional beverage. The above-mentioned beverage is not particularly limited as long as it contains an alcoholic extract of the bark mushroom as an active ingredient as an essential ingredient at the indicated ratio, and may be added with various flavors or natural carbohydrates as an additional ingredient ≪ / RTI > Examples of such natural carbohydrates include monosaccharides such as disaccharides such as glucose and fructose such as maltose, sucrose and the like and polysaccharides such as dextrins, cyclodextrins and the like, and Xylitol, sorbitol, and erythritol. Natural flavors (tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above The ratio of the natural carbohydrate may be generally about 1 to 20 g, preferably 5 to 12 g per 100 ml of the composition of the present invention. In addition, the composition of the present invention may be used for natural fruit juice, fruit juice drink, And may further contain flesh for manufacture.

In addition to the above, the health functional food of the present invention may contain various kinds of nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and heavies (cheese, chocolate etc.), pectic acid and its salts, And salts thereof, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. These components can be used independently or in combination. The proportion of such additives is not critical, but may be selected in the range of 0 to 20 parts by weight per 100 parts by weight of the alcohol extract of the present invention.

In the present specification, functional beverages are used to control the bio-defense rhythm of the beverage group or beverage composition to which the added value is imparted so that the function of the beverage functions for a specific purpose by using physical, biochemical, biotechnological techniques, Means a beverage which has been designed so that the body control function related to restoration and the like is sufficiently expressed in the living body.

The functional beverage is not particularly limited to the other components other than the alcoholic extract of the present invention as an essential ingredient in the indicated ratios and may contain various flavors or natural carbohydrates as an additional ingredient can do. Examples of such natural carbohydrates include monosaccharides such as disaccharides such as glucose and fructose such as maltose, sucrose and the like and polysaccharides such as dextrins, cyclodextrins and the like, and xylitol , Sorbitol, and erythritol. Natural flavors (tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably 5 to 12 g per 100 ml of the composition of the present invention.

In addition, in a health functional food for the purpose of improving or preventing hyperlipidemia or obesity, the amount of the extract may be 0.01 to 15% by weight of the total food, and the beverage composition may contain 0.02 to 5 g , Preferably 0.3 to 1 g.

According to another embodiment of the present invention, there is provided a method for preparing an alcoholic extract of Alaska pollack as described above.

The method for preparing an alcoholic extract of Alaska pollack according to an embodiment of the present invention includes the steps of preparing Alaskan mushroom, mixing the Alaskan mushroom with an alcohol having 1 to 10 carbon atoms, At a temperature of 20 to 60 DEG C for 12 to 36 hours.

Meanwhile, in the method for producing an alcoholic extract having 1 to 10 carbon atoms in the mushroom of the present invention, the alcohol is an alcohol having 1 to 5 carbon atoms, more preferably ethanol, most preferably 90 to 99.9 % (v / v) ethanol. When extracted with such an extraction solvent, it was found that cholesterol from the digestive tract and the effect of reducing the amount of fat absorption from the digestive tract were remarkably exhibited in addition to the effect of inhibiting digestion and absorption of cholesterol and inhibiting digestion and absorption of fat in the extracted extract. The specific extraction time, the extraction temperature, and the mixing ratio of the bark mushroom and the extraction solvent are different from those described above.

The composition of the present invention comprising an alcohol extract of Alaska pollack mushroom as an active ingredient inhibits the activity of pancreatic cholesterol esterase and pancreatic lipase to inhibit digestion and absorption of cholesterol, fat, or both to treat or prevent hyperlipidemia Can be usefully used for the prophylactic use and the therapeutic or prophylactic use of obesity.

FIG. 1 is a graph showing the inhibitory activity of pancreatic cholesterol esterase in the alcohol extract of Alaska pollack mushroom compared with the control.
FIG. 2 is a graph showing the inhibitory activity of pancreatic lipase in the alcohol extract of Alnus japonica against the control.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, the structure and effects of the present invention will be described in detail with reference to specific embodiments of the present invention. It should be understood, however, that the following examples are provided for a better understanding of the invention and are not to be construed as limiting the scope of the invention.

Hereinafter, the present invention will be described in detail with reference to examples.

EXAMPLES: Preparation of Alaska pollack mushroom alcohol extract

Fifty milliliters of alcohol was extracted with 2 g of dried Clavicorona pyxidata powder obtained from Gyeongsangbuk - do Research Institute for Forest Environment and then extracted with 20 ml of shaking incubator at 37 ℃ for 24 hours. The supernatant of the shaking incubator was centrifuged at 2500 rpm for 10 minutes, then the extract of Alaska pollack mushroom alcohol was collected and stored at -20 ° C.

Experimental Example:

1. Measurement and Results of Pancreatic Cholesterol Ester Raise Activity by Alcohol Extract

Pancreatic cholesterol esterase plays a role in recognizing acyl chain-bearing substrates as non-specific and isolating acyl chains. In order to measure the activity of pancreatic cholesterol ester raising by the mushroom alcohol extract of mushroom of the Examples, a poison pancreatic cholesterol ester raise made in Sigma chemical was used as an enzyme. Pancreatic cholesterol esterase cleaved the chromo-genic substrate (p-nirophenylbutyrate), and the activity of the enzyme was confirmed by color reaction. The inhibitory effect of the enzyme was measured by the change of absorbance at 405 nm using a microplate reader and expressed as% based on the absorbance at 405 nm of the extract-untreated group.

The activity of the enzyme was determined by the extract of Alaska pollack mushroom alcohol of the present invention. As a result, it was confirmed that the extract of Alaska pollack mushroom alcohol lowered the pancreatic cholesterol ester raising activity. The results are briefly shown in Fig.

2. Measurement and Results of Pancreatic Lipase Activity by Alcohol Extract

Pancreatic lipase plays a role in recognizing acyl chain-bearing substrates nonspecifically and isolating acyl chains. Porcine pancreatic lipase (Type II, Sigma chemical), an enzyme produced by Sigma Chemical, was used to measure the activity of pancreatic lipase by alfalfa extract. Using pancreatic lipase's ability to decompose chromo-genic substrate (p-nirophenylbutyrate), the activity of the enzyme was confirmed through color development. The inhibitory effect of the enzyme was measured by the change of absorbance at 405 nm using a microplate reader and calculated as% based on the absorbance at 405 nm of the untreated group of Allium tuberosum L. extract. The activity of the enzyme was determined by the extract of Alaska pollack mushroom alcohol. As a result, it was confirmed that the extract of Alaska pollack mushroom alcohol decreased the activity of pancreatic lipase. The results are briefly shown in Fig.

Preparation Example: Preparation using a mushroom alcohol extract

Production Example 1. Preparation of powder

20 mg of powdery mushroom alcohol extract, 100 mg of lactose, 10 mg of talc.

The above ingredients were mixed and filled in an airtight container to prepare powders.

Production Example 2. Preparation of tablets

100 mg of corn starch, 100 mg of lactose, 2 mg of magnesium stearate.

After mixing the above components, tablets were prepared by tableting according to the usual preparation method of tablets.

Production Example 3. Preparation of capsules

10 mg of powdered mushroom alcohol extract, 3 mg of crystalline cellulose, 14.8 mg of lactose, and 0.2 mg of magnesium stearate.

The above components were mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.

Production Example 4. Production of liquid agent

20 mg of powdery mushroom alcohol extract, 10 g of isomerized sugar, 5 g of mannitol, and purified water.

Each component was added to purified water in accordance with the usual liquid preparation method and dissolved, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was adjusted to 100 ml with purified water, And sterilized to prepare a liquid preparation.

Production Example 5. Production of Health Food

Vitamin B acetate 0.2 mg, Vitamin C 10 mg, Vitamin C 0.1 mg, Vitamin B 0.13 mg, Vitamin B 0.15 mg, Vitamin B12 0.5 mg, Vitamin B12 0.2 mg, Vitamin A acetate 70 mg, Vitamin A acetate 70 mg, 10 ㎍ of biotin, 1.7 ㎎ of nicotinic acid amide, 50 ㎍ of folate, 0.5 mg of calcium pantothenate, 1.75 mg of ferrous sulfate, 0.82 mg of zinc oxide, 25.3 mg of magnesium carbonate, 15 mg of potassium phosphate, 55 mg of potassium citrate, 90 mg of potassium citrate, 100 mg of calcium carbonate, and 24.8 mg of magnesium chloride.

Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.

Claims (20)

A pharmaceutical composition for the treatment or prevention of hyperlipidemia comprising an alcohol extract having 1 to 10 carbon atoms of alfalfa as an active ingredient. The composition of claim 1, wherein the alcohol is an alcohol having from 1 to 5 carbon atoms. The composition of claim 1, wherein the alcohol is ethanol. 4. The composition of claim 3, wherein the ethanol is 90 to 99.99% (v / v). The composition according to any one of claims 1 to 4, wherein the extract is obtained by extracting bark mallow from 90 to 99.99% (v / v) ethanol at a temperature of 20 to 60 DEG C for 12 to 36 hours . The composition according to claim 1 or 2, wherein the extract is obtained by mixing 0.1 to 20 g of a mushroom per 100 ml of an alcohol having 1 to 5 carbon atoms. The composition according to claim 1 or 2, wherein the composition comprises 0.001 to 50% by weight of an alcoholic extract having 1 to 5 carbon atoms in the mushroom. The composition according to any one of claims 1 to 4, wherein the extract inhibits the activity of pancreatic cholesterol ester raise. The composition according to any one of claims 1 to 4, wherein the extract inhibits the activity of pancreatic lipase. A medicament for the treatment or prevention of hyperlipidemia comprising an alcoholic extract having a carbon number of 1 to 10 of the alfalfa mushroom as an active ingredient. 11. The medicament according to claim 10, wherein the medicament is a powder, a granule, a tablet, a suspension, an emulsion, or a syrup. A health functional food for improving or preventing hyperlipidemia, which comprises an alcohol extract having 1 to 10 carbon atoms in a mushroom as an active ingredient. 13. The health functional food according to claim 12, wherein the health functional food is food, food additive or beverage. A method for treating or preventing hyperlipidemia comprising administering an effective amount of a pharmaceutically effective amount of an alcoholic extract of 1 to 10 carbon atoms in a mushroom to an animal other than a human. delete delete A method for preparing a composition for the treatment or prevention of hyperlipidemia by evaporating and drying an extract obtained by mixing a dried bark mushroom with an alcohol having 1-10 carbon atoms. [18] The method according to claim 17, wherein the extract is obtained by extracting dried mushroom mushroom and an alcohol having 1-10 carbon atoms in a shaking incubator. 19. The method according to claim 18, characterized in that the supernatant of the shake incubator is centrifuged to obtain an extract. A pharmaceutical composition for the treatment or prevention of obesity comprising an alcohol extract having 1 to 10 carbon atoms in a mushroom as an active ingredient.

Images